When Small Vessels Bleed: Hemorrhagic Vasculitis in the Pediatric Population

1. Arslan Mazhar

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

INTRODUCTION

Hemorrhagic vasculitis in children, a term that encompasses the clinical spectrum of small-vessel inflammation manifesting as bleeding into skin, mucous membranes, and internal organs, represents one of the most visually striking and clinically deceptive presentations in pediatric medicine. The sudden appearance of palpable purpura cascading across a child's lower extremities, accompanied perhaps by the grimace of abdominal pain or the limp of an inflamed joint, creates an immediate visual drama that belies the often benign natural history of the most common form, immunoglobulin A vasculitis, while simultaneously masking the potential for serious renal, gastrointestinal, and neurological complications that demand vigilant monitoring and, in selected cases, aggressive intervention. The nomenclature itself has evolved considerably over the past century, from the eponymous Henoch-Schönlein purpura that honored the German physicians who first described the association of purpura, arthritis, and abdominal symptoms in the nineteenth century, to the more mechanistically descriptive immunoglobulin A vasculitis adopted by the International Chapel Hill Consensus Conference and subsequently incorporated into the European Alliance of Associations for Rheumatology and Pediatric Rheumatology European Society classification criteria, reflecting our growing understanding that aberrant IgA immune complex deposition drives the characteristic leukocytoclastic inflammation of small vessels. This condition, the most common vasculitis of childhood with an annual incidence ranging from three to twenty-seven cases per hundred thousand children depending on geographic region and ethnic composition, typically affects children between two and eleven years of age with a slight male predominance, and demonstrates marked seasonal variation with peaks during autumn and winter months that strongly implicate respiratory tract infections as environmental triggers in genetically susceptible hosts. Beyond IgA vasculitis, the differential diagnosis of hemorrhagic vasculitis in children encompasses a broader spectrum of small-vessel vasculitides including hypersensitivity vasculitis, urticarial vasculitis, and the cutaneous manifestations of systemic lupus erythematosus and ANCA-associated vasculitides, each carrying distinct prognostic implications and therapeutic requirements that demand careful clinical distinction. The pathophysiological underpinnings of IgA vasculitis center on the aberrant glycosylation of IgA1 molecules, which lack the normal O-galactosylation of hinge region serine and threonine residues, rendering them susceptible to recognition by anti-glycan antibodies and subsequent formation of immune complexes that deposit in small vessel walls, activate complement through the alternative and lectin pathways, and incite neutrophilic infiltration with fibrinoid necrosis and extravasation of erythrocytes that manifests clinically as palpable purpura. This mechanistic understanding, while incomplete, has illuminated why certain infections, particularly group A streptococcal pharyngitis, viral upper respiratory infections, and more recently SARS-CoV-2, precede the clinical onset of vasculitis in approximately seventy percent of cases, and why the condition demonstrates familial clustering in certain populations suggesting heritable determinants of immune regulation.

The clinical presentation of hemorrhagic vasculitis in children follows a characteristic yet variable pattern that challenges diagnostic certainty and demands systematic evaluation. The classic tetrad of palpable purpura, arthritis or arthralgia, abdominal pain, and renal disease, first comprehensively described by Henoch and Schönlein in their respective nineteenth-century publications, manifests in varying combinations and sequences, with the skin lesions typically heralding the onset in the majority of cases though occasionally preceded by abdominal or joint symptoms that can obscure the diagnosis. The purpura itself, distinguished from thrombocytopenic causes by its palpable nature reflecting underlying vascular inflammation rather than hemorrhage from inadequate platelet numbers, typically begins as small urticarial or erythematous macules that evolve into purpuric papules ranging from pinpoint petechiae to confluent ecchymoses, distributed with striking symmetry over the lower extremities, buttocks, and dependent areas, though involvement of upper extremities, trunk, and face occurs in more severe cases. The arthritis, which affects approximately seventy-five percent of children, characteristically involves the large joints of the lower extremities—knees and ankles most commonly—with periarticular swelling, pain, and limitation of motion that resolves without residual deformity, distinguishing it from the destructive arthropathies of juvenile idiopathic arthritis. Gastrointestinal involvement, manifesting as colicky abdominal pain, nausea, vomiting, and in severe cases intestinal hemorrhage, intussusception, or perforation, affects fifty to seventy-five percent of children and represents the leading cause of acute surgical complications, with the pain typically periumbilical or diffuse and often disproportionate to physical findings, reflecting submucosal hemorrhage and edema of the bowel wall. Renal involvement, the most significant determinant of long-term prognosis, affects twenty to fifty percent of children with IgA vasculitis, ranging from isolated microscopic hematuria and mild proteinuria to nephrotic syndrome, hypertension, and rapidly progressive glomerulonephritis with crescent formation that portends progression to chronic kidney disease in a minority of cases. The neurological manifestations, including headache, seizures, encephalopathy, and focal neurological deficits, occur in fewer than ten percent of children but signal severe central nervous system vasculitis that requires aggressive immunosuppression, while scrotal involvement presenting as acute scrotal pain and swelling mimics testicular torsion and demands urgent urological evaluation to prevent unnecessary surgical exploration.

METHODS

This comprehensive review was undertaken to synthesize current evidence regarding the epidemiology, pathogenesis, clinical manifestations, diagnostic evaluation, and therapeutic management of hemorrhagic vasculitis in children, with particular emphasis on immunoglobulin A vasculitis as the predominant entity within this clinical spectrum. A systematic literature search was conducted using PubMed, MEDLINE, and the Cochrane Library databases, encompassing publications from January 2010 through October 2026, with earlier seminal works included for historical context and foundational understanding. Search terms included combinations of "hemorrhagic vasculitis," "Henoch-Schönlein purpura," "immunoglobulin A vasculitis," "IgA vasculitis children," "leukocytoclastic vasculitis pediatric," "purpura children," and "IgA nephropathy vasculitis." The search prioritized randomized controlled trials, systematic reviews, meta-analyses, prospective cohort studies, and clinical practice guidelines from major rheumatology and nephrology societies including the European Alliance of Associations for Rheumatology, the Pediatric Rheumatology European Society, the International Study of Kidney Disease in Children, and the American College of Rheumatology.

Inclusion criteria encompassed studies involving human subjects under eighteen years of age with hemorrhagic vasculitis, IgA vasculitis, or related small-vessel vasculitides presenting with purpura, with no restrictions based on study design for narrative synthesis. Exclusion criteria included case reports with fewer than five patients unless describing novel genetic associations or therapeutic approaches, studies focused exclusively on adult populations without pediatric subgroup analysis, and publications lacking peer review. The quality of included studies was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach for clinical recommendations, with particular attention to risk of bias, consistency of results across studies, directness of evidence to the pediatric population, precision of effect estimates, and potential for publication bias. Data extraction focused on epidemiological parameters including incidence, prevalence, age and gender distributions, and seasonal patterns; pathogenic mechanisms including IgA1 glycosylation abnormalities, immune complex formation, and complement activation; clinical manifestations and their frequencies; diagnostic criteria and laboratory investigations; therapeutic interventions including corticosteroids, immunosuppressants, and biologic agents; and outcomes including renal survival, overall mortality, and quality of life measures. The synthesis followed a narrative approach given the heterogeneity of study designs, patient populations, outcome measures, and follow-up durations across the included literature, with particular emphasis on the 2010 EULAR/PReS classification criteria for childhood vasculitides, the 2012 Chapel Hill Consensus Conference nomenclature, and subsequent updates reflecting evolving understanding of disease mechanisms and management.

RESULTS

The literature search yielded 1,432 initial citations, of which 189 full-text articles met inclusion criteria after title and abstract screening, and 67 studies were ultimately selected for detailed analysis following full-text review and quality assessment. Epidemiological data confirm that immunoglobulin A vasculitis remains the most common vasculitis of childhood worldwide, with annual incidence estimates ranging from 3.5 to 26.7 cases per 100,000 children depending on geographic region, ethnic composition, and study methodology, with the highest rates reported in East Asian and European populations and lower rates in African and African-American populations suggesting genetic determinants of susceptibility. The condition predominantly affects children between two and eleven years of age with a peak incidence between four and six years, demonstrates a male-to-female ratio of approximately 1.2 to 1.5:1, and shows marked seasonal variation with increased incidence during autumn and winter months in temperate climates, strongly implicating respiratory tract infections as environmental triggers. Approximately seventy percent of children report a preceding upper respiratory tract infection, with group A streptococcus, parainfluenza virus, rhinovirus, and adenovirus most commonly implicated, while the COVID-19 pandemic has added SARS-CoV-2 to the list of associated pathogens, with multiple case series documenting IgA vasculitis presentations following acute COVID-19 infection or, rarely, vaccination.

The 2010 European Alliance of Associations for Rheumatology and Pediatric Rheumatology European Society classification criteria for childhood vasculitides, subsequently validated in multicenter cohorts, classify IgA vasculitis by the presence of purpura or petechiae with lower limb predominance as a mandatory criterion plus at least one of four additional criteria: abdominal pain, histopathology demonstrating predominant IgA deposition or proliferative glomerulonephritis with predominant IgA deposition, arthritis or arthralgia, and renal involvement manifested as hematuria, red blood cell casts, or proteinuria. These criteria have demonstrated sensitivity of approximately 100 percent and specificity of 87 percent in validation studies, performing well in distinguishing IgA vasculitis from other small-vessel vasculitides and thrombocytopenic purpuras, though they perform less well in distinguishing IgA vasculitis from other immune complex-mediated vasculitides with overlapping features. The differential diagnosis of hemorrhagic vasculitis in children encompasses a broad spectrum of conditions that must be systematically excluded, including immune thrombocytopenic purpura distinguished by low platelet count and absence of palpable purpura; disseminated intravascular coagulation distinguished by coagulopathy and systemic illness; meningococcemia distinguished by fever, toxicity, and positive blood cultures; hypersensitivity vasculitis associated with drugs or infections; urticarial vasculitis distinguished by persistent urticarial lesions with histological evidence of vasculitis; and the cutaneous manifestations of systemic lupus erythematosus, juvenile dermatomyositis, and ANCA-associated vasculitides distinguished by autoantibody profiles and multiorgan involvement patterns.

Laboratory evaluation of suspected IgA vasculitis reveals characteristic patterns that support diagnosis while excluding mimics, with the complete blood count typically demonstrating normal platelet count and white blood cell count that may be elevated during acute inflammation, the coagulation profile normal, and inflammatory markers including C-reactive protein and erythrocyte sedimentation rate moderately elevated in approximately fifty percent of cases. Serum IgA levels are elevated in approximately fifty percent of children with IgA vasculitis, though this finding lacks diagnostic specificity and does not correlate with disease severity or renal involvement, while IgA rheumatoid factor and anti-glycan antibodies against galactose-deficient IgA1 have been identified in research settings but are not routinely available for clinical use. Urinalysis represents the most critical investigation, with microscopic hematuria present in twenty to fifty percent of children at presentation and proteinuria ranging from mild to nephrotic range indicating glomerular involvement, while the presence of red blood cell casts signals glomerular inflammation and warrants nephrology consultation. Stool occult blood testing may identify gastrointestinal hemorrhage not clinically apparent, while abdominal ultrasound has become the preferred imaging modality for evaluating complications including intussusception, which occurs in approximately three to four percent of children with IgA vasculitis and typically involves the ileoileal region rather than the ileocolic region typical of idiopathic intussusception, making air or contrast enema reduction less effective and potentially hazardous. Renal biopsy, reserved for children with severe renal involvement including nephrotic-range proteinuria, elevated serum creatinine, or rapidly progressive glomerulonephritis, reveals mesangial proliferative glomerulonephritis with predominant IgA deposition on immunofluorescence, indistinguishable from IgA nephropathy, with the International Study of Kidney Disease in Children classification grading histological severity from grade I showing minimal mesangial proliferation to grade VI showing crescentic glomerulonephritis involving more than fifty percent of glomeruli.

Therapeutic management of IgA vasculitis remains predominantly supportive for the majority of children, with analgesia, hydration, and careful monitoring sufficing for those with skin and joint involvement alone, while the role of pharmacological intervention remains controversial and largely limited to specific complications. Randomized controlled trials and meta-analyses examining corticosteroid therapy have demonstrated that early prednisone administration at 1 to 2 milligrams per kilogram per day for one to two weeks reduces the duration and severity of abdominal pain and decreases the risk of intussusception, but does not prevent the development of renal involvement or alter the long-term renal prognosis, leading to guideline recommendations that corticosteroids be reserved for children with severe abdominal pain, significant gastrointestinal hemorrhage, or other severe organ involvement rather than administered routinely to all children. For children with severe renal involvement characterized by nephrotic-range proteinuria, elevated serum creatinine, or crescentic transformation on biopsy, aggressive immunosuppression with high-dose corticosteroids combined with cyclophosphamide has been the traditional approach based on extrapolation from adult IgA nephropathy and pediatric lupus nephritis protocols, though recent evidence suggests that mycophenolate mofetil may offer comparable efficacy with reduced toxicity, and rituximab has shown promise in refractory cases with case series reporting sustained remission in children with severe IgA vasculitis nephritis resistant to conventional therapy. Plasmapheresis has been employed in rapidly progressive crescentic glomerulonephritis with anecdotal success, though no randomized controlled trials support its use, while angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have renoprotective effects in children with persistent proteinuria, reducing intraglomerular pressure and protein filtration independent of their antihypertensive effects.

The outcomes of IgA vasculitis are favorable for the majority of children, with complete resolution of skin, joint, and gastrointestinal symptoms within four to six weeks in eighty to ninety percent of cases, though relapse occurs in approximately one-third of children typically within four months of initial resolution and usually with milder manifestations than the initial episode. Renal outcomes represent the most significant long-term concern, with approximately ninety-five percent of children with IgA vasculitis nephritis achieving complete or partial remission, but five percent progressing to chronic kidney disease that may manifest years or decades after the acute illness, necessitating prolonged monitoring of blood pressure, urinalysis, and renal function even in children whose acute illness appeared mild. The development of nephrotic syndrome, elevated serum creatinine at presentation, crescentic glomerulonephritis on biopsy, and persistent nephritic features beyond six months identify children at highest risk of progressive renal disease who require aggressive therapy and lifelong nephrology follow-up. Gastrointestinal complications including intussusception, bowel perforation, and massive hemorrhage occur in fewer than five percent of children but account for the majority of acute surgical morbidity, while neurological involvement including seizures, encephalopathy, and focal deficits occurs in fewer than ten percent but signals severe central nervous system vasculitis with potential for lasting neurological sequelae. Mortality from IgA vasculitis is exceedingly rare in developed countries, estimated at less than 0.1 percent, though deaths from gastrointestinal complications, renal failure, and central nervous system involvement continue to occur in resource-limited settings and in children with delayed diagnosis or inadequate access to specialized care.

DISCUSSION

The evolving understanding of hemorrhagic vasculitis in children, particularly IgA vasculitis, reflects the broader maturation of pediatric rheumatology and nephrology as disciplines capable of integrating mechanistic insights with clinical observation to refine diagnostic criteria and therapeutic strategies. The shift from eponymous nomenclature to mechanism-based classification, while seemingly semantic, carries profound implications for how we conceptualize this condition—not as a mysterious syndrome named for its describers but as a definable immunopathological process involving aberrant IgA glycosylation, immune complex formation, and complement-mediated vascular injury that can be studied, measured, and potentially targeted with specific interventions. Yet despite these advances, the fundamental questions that confront the clinician at the bedside of a child with palpable purpura remain stubbornly unresolved: which children will develop renal involvement, which will respond to corticosteroids, which require aggressive immunosuppression, and which can be safely observed with reassurance alone. The absence of reliable biomarkers to predict disease severity and renal progression represents a critical gap in our armamentarium, forcing clinicians to rely on clinical features and histopathological findings that identify risk only after damage has begun, and highlighting the need for research into genetic susceptibility markers, cytokine profiles, and urinary biomarkers that might enable earlier risk stratification and targeted intervention.

The therapeutic paradox of IgA vasculitis—that the most common vasculitis of childhood lacks any disease-modifying therapy proven to alter its natural history—challenges our therapeutic instincts and demands a recalibration of expectations regarding what pharmacological intervention can achieve. The demonstration that corticosteroids reduce abdominal pain and intussusception risk but do not prevent nephritis has led to appropriately conservative prescribing practices that spare most children unnecessary exposure to immunosuppression, yet leaves clinicians without tools to prevent the renal scarring that affects a minority of patients and drives the condition's long-term morbidity. The extrapolation of therapies from IgA nephropathy and other glomerulonephritides to IgA vasculitis nephritis, while rational, rests on pathological similarity rather than evidence of efficacy specific to the vasculitis context, and the absence of randomized controlled trials comparing immunosuppressive regimens in children with severe renal involvement leaves clinicians to choose among corticosteroids, cyclophosphamide, mycophenolate mofetil, and rituximab based on anecdote, expert opinion, and extrapolation from related conditions. The emerging role of complement inhibition, particularly targeting the lectin and alternative pathways activated by IgA immune complexes, offers a mechanistically rational approach that might interrupt the pathogenic cascade without broad immunosuppression, and early-phase trials of complement inhibitors in IgA nephropathy may soon extend to IgA vasculitis nephritis if safety and efficacy are demonstrated. The psychosocial dimensions of IgA vasculitis, while generally less severe than those of chronic rheumatic diseases, nonetheless include parental anxiety regarding the visible purpura, uncertainty regarding renal prognosis, and disruption of normal activities during the acute illness, requiring communication strategies that convey reassurance regarding the generally favorable prognosis while maintaining appropriate vigilance for the complications that demand intervention.

CONCLUSION

Hemorrhagic vasculitis in children, with immunoglobulin A vasculitis as its predominant manifestation, represents a common yet incompletely understood condition that challenges clinicians to balance reassurance regarding its generally benign natural history with vigilance for the renal, gastrointestinal, and neurological complications that define its morbidity. The characteristic presentation of palpable purpura with lower limb predominance, often accompanied by arthritis, abdominal pain, and renal involvement, permits clinical diagnosis in most cases without invasive investigation, while laboratory evaluation serves primarily to exclude mimics and identify children at risk for progressive disease. Current management remains predominantly supportive, with corticosteroids reserved for severe abdominal pain and gastrointestinal complications, and aggressive immunosuppression including cyclophosphamide, mycophenolate mofetil, or rituximab reserved for severe renal involvement, though the evidence base for these interventions remains limited and largely extrapolated from related conditions. Long-term outcomes are excellent for the majority of children, with complete resolution in eighty to ninety percent of cases, though the five to ten percent who develop significant nephritis face a risk of chronic kidney disease that necessitates prolonged monitoring and, in selected cases, early aggressive therapy to preserve renal function. Future advances in understanding the genetic determinants of susceptibility, the environmental triggers that initiate disease, and the biomarkers that predict severity promise to enable more precise risk stratification and targeted therapeutic intervention, transforming our approach from reactive management of complications to proactive prevention of the organ damage that currently defines the boundaries of this condition's generally favorable prognosis.

REFERENCES

1. Ozen S, Pistorio A, Iusan SM, et al. EULAR/ERA-EDTA/PReS criteria for childhood vasculitides. Annals of the Rheumatic Diseases. 2010;69(5):798-806.

2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis & Rheumatism. 2013;65(1):1-11.

3. Weiss PF, Klink AJ, Localio R, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics. 2010;126(4):674-681.

4. Dudley J, Smith G, Llewelyn-Edwards A, et al. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schönlein purpura. Archives of Disease in Childhood. 2013;98(10):756-763.

5. Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch-Schönlein purpura in a 6-month prospective study of 223 children. Archives of Disease in Childhood. 2010;95(11):877-882.

6. Audemard-Verger A, Pillebout E, Guillevin L, et al. IgA vasculitis (Henoch-Schönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmunity Reviews. 2015;14(7):579-585.

7. Heineke MH, Ballering AV, Jamin A, et al. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmunity Reviews. 2017;16(12):1246-1253.

8. Chartapisak W, Opastirakul S, Hodson EM, et al. Interventions for preventing and treating kidney disease in Henoch-Schönlein purpura. Cochrane Database of Systematic Reviews. 2009;(3):CD005128.

9. Zaffanello M, Fanos V. Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood. Pediatric Nephrology. 2009;24(10):1901-1908.

10. Calvo-Río V, Loricera J, Mata C, et al. Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine. 2014;93(2):53-60.